Accéder au contenu
MilliporeSigma

Principaux documents

Voir toute la documentation

SFRVN

Sf-RVN® Insect Cell Line

Synonyme(s) :

Sf9 rhabdovirus-negative (Sf-RVN®) Insect Cell Line

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

UNSPSC Code:
41116105
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

description

Sf9 rhabdovirus-negative (Sf-RVN®) Insect Cell Line

solubility

DMSO: 10%

shipped in

liquid nitrogen

storage temp.

−196°C

General description

Sf-RVN® cells are provided to customers in vials containing 1 mL at 10 x 106 cells/mL. Cells are banked in EX-CELL® CD Insect Cell Medium and 10% DMSO.
The Sf-RVN® Insect Cell Line is a rhabdovirus-negative Sf9 cell line that can be grown in both adherent and suspension culture. Sf-RVN® Insect Cell Line has been adapted for growth in chemically defined medium to be used for the production of recombinant proteins, adeno-associated viruses (AAV) and viral-like particles (VLP). The cell line was tested for adventitious agents and banked under GMP conditions. A technical user guide, with detailed protocols for optimal performances, is provided with the cell line.The EX-CELL® CD Insect Cell Medium, recommended for use, is optimized to get excellent growth and productivity of the Sf-RVN® Insect Cell Line. Combined, these two products form the Sf-RVN® Platform.

Cell Line Origin

Sf-RVN® is an insect cell line originally derived from ovarian tissue of Spodoptera frugiperda (Sf) pupae. The parental line, IPLB-SF-21 (renamed IPLB-SF-21 AE after adaptation into TC-100 medium), was established by J. Vaughn at the Insect Pathology Beltsville in Maryland, USA in the late 1960s. A subclone, designated Sf9, was established in 1983 by G. Smith and C. Cherry. Sf-RVN® was isolated from Sf9 by GlycoBac, LLC.

Physical form

Sf-RVN® cells are provided to customers in vials containing 1 mL at 10 x 106cells/mL. Cells are banked in EX-CELL® CD Insect Cell Medium and 10% DMSO

Other Notes

Sf-RVN® is an insect cell line originally derived from ovarian tissue of Spodoptera frugiperda (Sf) pupae. The parental line, IPLB-SF-21 (renamed IPLB-SF-21 AE after adaptation into TC-100 medium), was established by J. Vaughn at the Insect Pathology Beltsville in Maryland, USA in the late 1960s. A subclone, designated Sf9, was established in 1983 by G. Smith and C. Cherry. Sf-RVN® was isolated from Sf9 by GlycoBac, LLC.

Legal Information

EX-CELL is a registered trademark of Merck KGaA, Darmstadt, Germany
Sf-RVN is a registered trademark of Merck KGaA, Darmstadt, Germany

Classe de stockage

12 - Non Combustible Liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Articles

Can AAV Continue to Deliver the Promise of Gene Therapy?

The current status and future manufacturing of AAV-based gene therapies is discussed in this podcast transcript, including how to streamline large-scale manufacturing.

Virus-like Particle (VLP) Vaccine Bioprocessing and Formulation Steps

This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.

Cell and Gene Therapy Manufacturing: Upstream Processing for AAV and Lentivirus Platforms

Minimize the complexities of cell and gene therapy production. Switch to upstream viral vector platforms to enhance scalability and simplify GMP manufacturing.

Voir tous les articles

Contenu apparenté

Viral Vector Upstream Platforms

A transfection-based solution to viral vector production using a suspension cell line, chemically defined medium, and a process with proven performance at scale.

Plateformes upstream pour vecteurs viraux

Solution pour la production de vecteurs viraux basée sur la transfection, utilisant une lignée cellulaire en suspension, un milieu chimiquement défini et un procédé éprouvé à l'échelle réelle.